VACCINE

Current Drug Safety • March 2014
Human papilloma virus
vaccine associated uveitis
Author information
Holt HD, Hinkle DM, Falk NS, Fraunfelder FT, Fraunfelder FW1.
Lions Eye Institute, Albany Medical College, Slingerlands, New York, USA
hncl1983@gmail.com
Abstract
PURPOSE
To report a possible association between human papilloma virus (HPV) vaccination
and uveitis.
METHODS
Spontaneous reports from the National Registry of Drug-Induced Ocular Side effects,
World Health Organization and Food and Drug Administration were collected
on uveitis associated with human papilloma virus vaccination. A MEDLINE search
was performed using keywords “uveitis,” “iritis,” “iridocyclitis,” “human papilloma
virus,” “Cervarix”, and “Gardasil.”
MAIN OUTCOME MEASURES
Data garnered from spontaneous reports included the age, gender, adverse drug reaction
(ADR), date of administration, concomitant administration of other vaccinations,
time until onset of ADR, other systemic reactions, and dechallenge and rechallenge
data.
“A total of 24 case reports
of uveitis associated with human papilloma virus
vaccination were identified, all cases were female,
and the median age was 17. According to World Health
Organization criteria, the relationship between human
papilloma virus vaccination and uveitis is “possible.”
RESULTS
A total of 24 case reports of uveitis associated with human papilloma virus vaccination
were identified, all cases were female, and the median age was 17. Median time
from HPV vaccination to reported ADR was 30 days (range 0-476 days).
DISCUSSION
According to World Health Organization criteria, the relationship between human
papilloma virus vaccination and uveitis is “possible.” Causality assessments are
based on the time relationship of drug administration, uveitis development and rechallenge
data.
CONCLUSIONS
Clinicians should be aware of a possible bilateral uveitis and papillitis following
HPV vaccination.
http://www.ncbi.nlm.nih.gov/pubmed/24191906